Mergers & Acquisitions - Rare diseases, Research

Filter

Current filters:

Rare diseasesResearch

Popular Filters

Genzyme to gain rights to certain Alnylam rare disease pipeline products

Genzyme to gain rights to certain Alnylam rare disease pipeline products

13-01-2014

French drug major Sanofi’s US biotech subsidiary Genzyme and Alnylam Pharmaceuticals have significantly…

Alnylam PharmaceuticalsBiotechnologyGenzymeLicensingMergers & AcquisitionspatisiranRare diseasesResearchSanofi

Pharming considers options, including a sale of the company

13-06-2012

Netherland-based biotech company Pharming Group (NYSE Euronext: PHARM) yesterday revealed that it is…

BiotechnologyLicensingMergers & AcquisitionsPharmingRare diseasesResearchRuconest

Cushing’s syndrome patients to receive safer drug options

22-02-2012

New upcoming treatments for Cushing’s syndrome promise to improve patient’s quality of life,…

Corcept TherapeuticsHRA PharmaKorlymMergers & AcquisitionsMifedrenNovartisPharmaceuticalRare diseasesResearchSignifor

ViroPharma buys option to acquire Meritage Pharma

28-12-2011

ViroPharma (Nasdaq: VPHM) has entered into an exclusive option to acquire fellow USA based Meritage Pharma,…

BudesonideMergers & AcquisitionsMeritage PharmaPharmaceuticalRare diseasesResearchViroPharma

Back to top